<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656029</url>
  </required_header>
  <id_info>
    <org_study_id>007-2018</org_study_id>
    <nct_id>NCT03656029</nct_id>
  </id_info>
  <brief_title>Dose-response of Cannabis and Driving</brief_title>
  <official_title>Dose-dependent Effects of Smoked Cannabis on Simulated Driving Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidemiological studies have established a link between collisions while driving and cannabis&#xD;
      use. With the changing legal landscape around cannabis, there is much interest in determining&#xD;
      per se limits of cannabis while driving. The present study will evaluate driving on a driving&#xD;
      simulator after smoking placebo or cannabis with 3 different levels of THC. THC is the active&#xD;
      component in cannabis and blood, urine and oral fluid levels of THC will be correlated with&#xD;
      driving impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will attend the laboratory for 4 separate sessions, separated by about a week.&#xD;
      In each session, participants will receive one of 3 doses of smoked cannabis or a placebo.&#xD;
      Participants will not know which dose they are receiving. Participants will complete&#xD;
      questionnaires, do cognitive tests and drive on a driving simulator before and after smoking&#xD;
      the cannabis or placebo cigarette. Blood, urine and oral fluid will be collected throughout&#xD;
      the 7-8 hour session to determine levels of THC and its metabolites. These values will be&#xD;
      correlated with measures of driving impairment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This will be a within-subjects, counterbalanced, placebo-controlled study of placebo or 3 doses of cannabis</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean speed</measure>
    <time_frame>Change in speed of driving between the time before smoking the cigarette and either 30 or 90 minutes after smoking the cigarette</time_frame>
    <description>Speed of driving the simulator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard deviation of lateral position</measure>
    <time_frame>Change in measure from before smoking the cigarette to either 30 or 90 minutes after smoking</time_frame>
    <description>Driving measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reaction time</measure>
    <time_frame>Change in measure from before smoking the cigarette to either 30 or 90 minutes after smoking</time_frame>
    <description>Driving measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of THC and metabolites</measure>
    <time_frame>Change from before smoking cigarette to various time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours</time_frame>
    <description>Blood will be taken to determine how much THC entered the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral fluid concentrations of THC and metabolites</measure>
    <time_frame>Change from levels before smoking to 4 time points after smoking: 30 minutes, 90 minutes, 2 hours and 6 hours</time_frame>
    <description>Participants will provide oral fluid to determine how much THC is in the oral fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and Diastolic Blood pressure</measure>
    <time_frame>Change from before smoking to a number of time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Change from before smoking to a number of time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respirations</measure>
    <time_frame>Change from before smoking to a number of time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temperature</measure>
    <time_frame>Change from before smoking to a number of time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scales</measure>
    <time_frame>Change from before smoking to a number of time points after smoking: 5 minutes, 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2hours, 3 hours, 4 hours, 5 hours and 6 hours</time_frame>
    <description>Tests designed to assess the degree of subjective effects of the drug. The questions will be scored on a scale from 0 to 100 and will consist of: 'I like this drug effect', 'this feels like cannabis', 'I feel this effect', 'I feel this high', 'I feel the good effects', 'I feel the bad effects', 'I feel the rush'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal free recall test</measure>
    <time_frame>Change from pre-smoking levels to those observed 60 minutes after smoking</time_frame>
    <description>Test of memory: Participants will be asked to recall words that are read from a list</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Useful field of view</measure>
    <time_frame>Change from pre-smoking levels to those observed 60 minutes after smoking</time_frame>
    <description>A computer test for visual processing speed, selective and divided attention</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Driving Impaired</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Abuse Cannabis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will smoke a single smoked placebo (&lt;0.1% THC) cannabis cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will smoke a single low dose (6.25% THC) of smoked cannabis cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>middle dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will smoke a single intermediate dose (12.5% THC) of smoked cannabis cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will smoke a single high dose (22% THC) of smoked cannabis cigarette</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabis</intervention_name>
    <description>Participants will smoke as much of the cigarette as they wish</description>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_label>low dose</arm_group_label>
    <arm_group_label>middle dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will smoke a placebo cigarette</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Near daily use of cannabis (1-5 days/week) confirmed by self-report and urine&#xD;
             screening&#xD;
&#xD;
          -  Has held a class G2 or G licence (or equivalent from another jurisdiction) for at&#xD;
             least 12 months&#xD;
&#xD;
          -  Willing to abstain from using cannabis for 72 hours prior to each practice or test&#xD;
             session&#xD;
&#xD;
          -  Willing to abstain from alcohol for 48 hours prior to each session, and to abstain&#xD;
             from all other drugs not medically required for the duration of the study (beginning&#xD;
             48 hours prior to the practice session)&#xD;
&#xD;
          -  Provides written and informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of severe medical or psychiatric condition&#xD;
&#xD;
          -  Meets criteria for current or lifetime alcohol or other substance use disorder, except&#xD;
             tobacco use disorder and caffeine use disorder&#xD;
&#xD;
          -  Regular user of medication that may affect cognitive functioning and/or driver&#xD;
             performance&#xD;
&#xD;
          -  Family history of schizophrenia or other psychotic disorder&#xD;
&#xD;
          -  Pregnant, looking to become pregnant, or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruna Brands, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia Di Ciano, PhD</last_name>
    <phone>416 535-8501</phone>
    <phone_ext>34002</phone_ext>
    <email>patricia.diciano@camh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruna Brands, PhD</last_name>
    <phone>416 535-8501</phone>
    <phone_ext>36860</phone_ext>
    <email>bruna.brands@camh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 2S1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Le Foll, MD, PhD</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>33111</phone_ext>
      <email>bernard.lefoll@camh.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

